Login +0086-27-65522453 [email protected]

BKM120(NVP-BKM120, Buparlisib) Catalog No : 52207

Chemical Information

Product NameBKM120(NVP-BKM120, Buparlisib)
Iupac Chemical Name5-(2,6-dimorpholinopyrimidin-4-yl)-4-(trifluoromethyl)pyridin-2-amine 
SynonymsNVP-BKM120; NVP BKM-120; NVP BKM120; BKM-120; BKM120; BKM 120; Buparlisib 
Molecular FormulaC18H21F3N6O2 
Molecular Weight410.39 
SmileO1CCN(CC1)C1=NC(=CC(=N1)C=1C(=CC(=NC1)N)C(F)(F)F)N1CCOCC1
InChiKeyCWHUFRVAEUJCEF-UHFFFAOYSA-N
InChiInChI=1S/C18H21F3N6O2/c19-18(20,21)13-9-15(22)23-11-12(13)14-10-16(26-1-5-28-6-2-26)25-17(24-14)27-3-7-29-8-4-27/h9-11H,1-8H2,(H2,22,23)
Cas944396-07-0

Technical Data

Appearanceoff-white solid 
Purity98% 
SolubilitySoluble in DMSO to 20 mM 
Storage3 years -20ºCpowder 
Shipping ConditionShipped under ambient temperature 
Quality control

Description

BKM120(NVP-BKM120, Buparlisib) is an orally bioavailable specific oral inhibitor of the pan-class I phosphatidylinositol 3 kinase (PI3K) family of lipid kinases with potential antineoplastic activity. Buparlisib specifically inhibits class I PIK3 in the PI3K/AKT kinase (or protein kinase B) signaling pathway in an ATP-competitive manner, thereby inhibiting the production of the secondary messenger phosphatidylinositol-3,4,5-trisphosphate and activation of the PI3K signaling pathway. This may result in inhibition of tumor cell growth and survival in susceptible tumor cell populations. Activation of the PI3K signaling pathway is frequently associated with tumorigenesis. Dysregulated PI3K signaling may contribute to tumor resistance to a variety of antineoplastic agents. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus).

 

Chemical Structure

52207 - BKM120(NVP-BKM120, Buparlisib) | CAS 944396-07-0

Package

SizePrice
Login to get price

Quick Order

Change

Contact Us